• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Illumina, Merck launch test for cancer development, progression insights

Illumina, Merck launch test for cancer development, progression insights

June 22, 2022 By Sean Whooley

Illumina Merck research test genomic profiling tumors
[Image from Illumina/Merck]
Illumina (Nasdaq:ILMN) announced today that it launched a new research test, co-developed with Merck (NYSE:MRK).

The jointly developed test adds the assessment of a new genomic signature to the already distributed TruSight Oncology 500 assay, enabling researchers to unlock deeper insights about the tumor genome by identifying genetic mutations used in the evaluation of homologous recombination deficiency (HRD). HRD, a genomic signature, describes when cells are unable to effectively repair double-stranded DNA breaks, an occurrence that can lead to genomic instability and eventually tumor formation.

According to a news release, the new test will be made available globally, excluding the U.S. and Japan. The two companies originally announced that they partnered in September 2021 to develop and commercialize tests that identify genetic mutations used in the assessment of HRD.

“HRD status has emerged as an important biomarker in tumors that harbor high levels of DNA damage, such as ovarian, breast, prostate, and pancreatic cancers,” Illumina CMO Dr. Phil Febbo said in the release. “With one sample and one test, TruSight Oncology 500 HRD assay provides labs with comprehensive, accurate, sensitive results that can greatly enhance our understanding of the genomic nature of a tumor.”

The research use-only TruSight Oncology 500 HRD test uses next-generation sequencing from Illumina and validated HRD technology from Myriad Genetics to enable labs to accurately detect genomic instability and analyze more than 500 genes simultaneously, including those relevant to HRD status.

Technical University of Munich’s Molecular Pathology Diagnostic Unit participated in the TSO 500 HRD early access program to compare the results of Illumina’s prototype TSO 500 HRD assay to a validated reference standard from Myriad.

Large-cohort studies demonstrate that comprehensive genomic profiling (CGP) can potentially identify relevant genetic alterations in up to 90% of samples, Illumina said, with a single, comprehensive assay able to assess a wide range of biomarkers using less sample and returning results more quickly compared to multiple, iterative tests.

Illumina and Merck expect the research test to begin shipping globally, bar the U.S. and Japan, in August. They will also work to develop a new HRD companion diagnostic for the European Union and United Kingdom to aid in the detection of ovarian cancer patients with positive HRD status.

“We are pleased to reach this first milestone with Illumina to commercialize an assay for HRD assessment that will aid in advancing clinical research and broaden access to clinical trials,” Merck Research Laboratories SVP of Early Stage Development for Clinical Oncology Dr. Eric H. Rubin said.

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics, News Well, Oncology Tagged With: Illumina, Merck

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy